Cisplatin resistance remains a major therapeutic challenge in oral squamous cell carcinoma (OSCC), leading to treatment failure and poor outcomes. This study aimed to generate and characterize cisplatin-resistant OSCC models to elucidate resistance mechanisms. Two resistant OSCC cell lines (SCC-9R and HSC-3R) were developed through gradual dose escalation. Parental and resistant cells were analyzed via RNA-seq and gene set enrichment analysis, and validated through RT-qPCR, Western blot, immunofluorescence, and gelatin zymography. Functional assays, including 2D and 3D migration and invasion models, assessed phenotypic changes. A multi-omics analysis revealed molecular alterations in resistant cells, including 305 differentially expressed genes (DEGs) in HSC-3R (187 upregulated) and 782 in SCC-9R (298 upregulated) versus parental lines, with enrichment for extracellular matrix organization (p < 0.001) and consistent epithelial–mesenchymal transition (EMT) activation (p < 0.001), demonstrated by the upregulation of ZEB1, ZEB2, Vimentin, and TWIST1, and E-cadherin suppression. Functional validation confirmed an aggressive phenotype, including increased migration (p < 0.05), invasion (p < 0.01), and elevated MMP-2 (p < 0.01) and MMP-9 (p < 0.001) activity. Findings were verified in 3D spheroid models. Overall, cisplatin resistance in OSCC involves EMT, inflammatory signaling, and metabolic adaptation. The consistency of these features across both models supports the robustness of this in vitro system and reveals targets for therapeutic intervention.
Introduction: Colon cancer is a common disease, treated with few chemotherapeutic agents with similar treatment sequencing despite its heterogeneity. A significant proportion of patients are diagnosed with metastasis, and resistance to antineoplastic drugs is associated with disease progression and therapeutic failure. It is known that the tumor microenvironment plays an essential role in cancer progression, contributing to processes that may be associated with therapeutic resistance mechanisms in colon cancer. In this study, we aim to identify a gene expression signature and its relationship with immune cell infiltration in colon cancer, contributing to the identification of potential resistance biomarkers. Methods: An in silico study was conducted using RNA-seq data from The Cancer Genome Atlas Program (TCGA) samples, subdivided into two groups (treatment-resistant and non-resistant), taking into account the molecular subgroups (CMS1, CMS2, CMS3, and CMS4). The following algorithms were used: i. Limma was applied to identify differentially expressed genes; ii. WGCNA was applied to construct co-expression networks; iii. CIBERSORT was applied to estimate the proportion of infiltrating immune cells; and iv. TIMER was applied to explore the relationship between core genes and immune cell content. Results: Twenty differentially expressed genes (DEGs) were found, with 18 related to the group considered resistant to oncologic treatment and presenting poorer overall survival. T CD4 memory resting cells and M0 and M2 macrophages were found in more significant proportions in the analyzed samples and more infiltrated in the tumor microenvironment, the higher the expression of some of these resistance DEGs. Additionally, these genes correlate with biological aspects of neuronal differentiation, axogenesis, and synaptic transmission. Conclusion: The gene expression signature suggests the presence of differentially expressed synaptic membrane genes, which may be involved in neuronal pathways that influence the tumor microenvironment, potentially serving as future biomarkers. Furthermore, the presence of M0 and M2 macrophages and T CD4 memory resting cells suggests a potential interaction that may play a role in therapeutic resistance.
The global challenge posed by the prolonged COVID-19 pandemic underscores the critical need for ongoing genomic surveillance to identify emerging variants and formulate effective public health strategies. This retrospective observational study, conducted in a reference hospital in Northeast Brazil and comprising 2116 cases, employed PCR genotyping together with epidemiological data to elucidate the impact of the Gamma variant during its emergence, revealing distinct patterns in hospitalization rates, severity of illness, and outcomes. The study emphasizes the challenges posed by the variant, particularly an increased tendency for ICU admissions and respiratory support, especially among adults aged 18 to 59 without comorbidities. Laboratory analyses further demonstrate elevated inflammatory, coagulation, and hepatic markers in the Gamma variant cohort, suggesting a more severe systemic response. Despite limitations, including a retrospective approach and single-institution data, the study underscores the importance of ongoing genomic surveillance. Overall, this research contributes valuable insights into the impact of the Gamma variant on COVID-19 dynamics, advocating for continued research and surveillance to inform effective public health strategies regarding evolving viral variants.